Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 16;8(2):e001510. doi: 10.1136/jitc-2020-001510

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Specific proteins were preferentially recognized in patients with cancer and patients with mCRPC. (A) Heatmap depicting the difference in log2 fluorescence levels between each peptide in each patient and its grand mean across patients, displaying only the set of 6708 peptides that met the secondary selection criteria. Patients are grouped by stage across the x-axis, while peptides are clustered along the y-axis. (B) Waterfall plot depicting a gene ontology (GO) analysis of proteins that had significantly more antibody recognition in patients with cancer than controls. The top row indicates the GO term that encompasses the most genes corresponding to significant peptides. For the second row, these genes are then removed from the list and the GO term that encompasses the most genes in the remainder of the list is chosen. Genes identified by this process are counted along the x-axis to visualize overlapping GO terms. Waterfall plots depicting GO analysis of proteins that had significantly increased antibody responses in (C) patients with mCRPC compared with all other patients or (D) patients with nmCRPC compared with patients with nmCSPC. mCRPC, castration-resistant metastatic disease; nmCRPC, castration-resistant non-metastatic prostate cancer; nmCSPC, castration-sensitive non-metastatic prostate cancer.